Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Long-Term Data Show Consistent OS Benefit With Nivolumab Plus Ipilimumab in mNSCLC
The combination demonstrated durable survival benefits among patients with metastatic non–small cell lung cancer (mNSCLC) regardless of PD-L1 expression levels at a minimum follow-up of more than 6 years.
AML-Specific Early Mortality Risk Indices May Increase Accuracy of Care Quality Measurements
A study found acute myeloid leukemia (AML) salvage therapy was independently associated with early mortality compared with frontline therapy, suggesting that algorithms measuring quality of care should incorporate risk mortality indices that factor in disease characteristics and treatment status.
National Alliance Guideline Identifies Key PBM Concerns for Health Plan Purchasers
The playbook includes resources for purchasers to help in their dealings with pharmacy benefit managers (PBMs), including best practice checklists, sample questionnaires for choosing consultants, and recommendations for contracting language.
Study Suggests CAR T-Cell Therapy Safe, Effective After Allo-SCT in Multiple Myeloma
A retrospective analysis of the CARTITUDE-1 trial suggests that patients who have undergone allogeneic stem cell transplant (allo-SCT) prior to receiving chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma experience comparable outcomes to allo-SCT–naïve patients.
Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL
Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma
The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.
Axi-Cel Extends Survival vs Standard of Care for R/R LBCL
An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
Atorvastatin May Mitigate Risk of Cardiac Events Due to Anthracycline Use in Lymphoma
Anthracyclines are widely used to treat hematological and solid-tumor cancers, but past research suggests their use may be associated with late cardiac effects, including heart failure, among patients with lymphomas and other cancers.
ASCO 2023: Leukemia and Lymphoma
Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
Patients With CML Feel Shared Decision-Making Is Lacking, Want More Focus on QOL
Data from the Survey of Unmet Needs in Chronic Myeloid Leukemia (CML SUN) trial show that quality of life (QOL) and shared decision-making are priorities for patients, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Higher Spleen Volume at HSCT Associated With Worse Outcomes in AML
A recent study found that higher spleen volume before undergoing allogeneic hematopoietic stem cell transplantation (HSCT) was associated with worse overall survival and higher nonrelapse mortality incidence in patients with acute myeloid leukemia (AML).
Dr Wojciech Jurczak Discusses Changing Treatment Options for R/R DLBCL
Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discusses the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Common CVD Biomarkers May Hold Prognostic Value in MDS, Study Finds
The findings suggest that circulating N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15, both soluble biomarkers of cardiovascular disease (CVD), may be indicators of the course of myelodysplastic syndromes (MDS) and outcomes.
ePROM Monitoring of Patients With Inflammatory Arthritides May Be Beneficial, Review Suggests
Utilizing electronic patient-reported outcome measures (ePROMs) may hold potential to reduce health care resource utilization without affecting outcomes for patients with inflammatory arthritides, such as rheumatoid arthritis.
Study Explores Risk Factors for Therapy-Related MDS, AML Following HCT for Multiple Myeloma
The occurrence of treatment-related myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after autologous hematopoietic cell transplantation (HCT) for multiple myeloma was associated with aggressive disease characteristics and poor outcomes.
NCCN Guidelines Update Recommends Ropeginterferon Alfa-2b for Polycythemia Vera
Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.